Skip to main content
Premium Trial:

Request an Annual Quote

OGI Invests in Start-up Stem Cell Firm for 'Omics Studies

NEW YORK (GenomeWeb News) – The Ontario Genomics Institute said today that it has provided funding to Tissue Regeneration Therapeutics (TRT), a company developing umbilical stem cell-based treatments for a range of diseases, that will support 'omics-based research projects.

OGI and the company did not disclose the amount of the investment. The funds will support proteomic and transcriptomic analyses that will provide information the firm will need to gain the regulatory approval to conduct human clinical trials and to differentiate their product from competitors.

OGI provided the investment through its Pre-Commercialization Business Development Fund, which invests in genomics, proteomics, and associated technologies that are in the proof-of-principle phase.

Toronto-based TRT's technology seeks to use umbilical mesenchymal stem cells to treat conditions such as arthritis, diabetes, and Crohn's disease, among others, and it hopes to launch clinical trials within two years.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.